GlassScriptPhysician profile
Deborah Wallach
NPI 1326594144
$3,095.00
in general payments reported to CMS, 2019-2025
22 companies · $516 in 2025
The $516 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,143 · 2022: $386 · 2023: $577 · 2024: $473 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299 · Long Term Medical Supply Or Device Loan: $167 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.05 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,609.51 | 2021-2023 | |
| Abbvie INC. | $296.42 | 2023-2025 | |
| Genentech USA, INC. | $271.55 | 2023-2025 | Tecentriq, Venclexta, Polivy |
| Janssen Biotech, INC. | $206.08 | 2023-2025 | Erleada, Rybrevant, Akeega |
| Glaxosmithkline, LLC. | $106.66 | 2023-2024 | Zejula, Jemperli |
| Stemline Therapeutics INC. | $81.32 | 2023-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $78.61 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $74.67 | 2023 | |
| Karyopharm Therapeutics INC. | $62.50 | 2021 | |
| Array Biopharma INC | $40.91 | 2021-2025 | Mektovi, Tukysa, Braftovi |
| Springworks Therapeutics, INC. | $39.53 | 2025 | Ogsiveo |
| Genzyme Corporation | $35.48 | 2024 | |
| Blueprint Medicines Corporation | $29.03 | 2022 | |
| Daiichi Sankyo INC. | $27.77 | 2023 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $22.81 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.41 | 2025 | |
| Mylan Institutional INC. | $19.66 | 2023 | Ogivri, Fulphila |
| Celgene Corporation | $18.58 | 2025 | Reblozyl |
| Apellis Pharmaceuticals, INC. | $14.98 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2025 | Alunbrig |
| Beigene USA, INC. | $12.00 | 2022 | |
| Tactile Systems Technology INC | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Wallach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.